Prescription medicine
Galantamine First approved as Razadyne
Galantamine (Razadyne) is a prescription medicine with an FDA approval on record since 2001. FDA's NDC Directory lists it from 9 generic labelers, and pharmacies paid $0.294 per galantamine hbr 4 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the galantamine FDA label on DailyMed (effective June 1, 2026, Slate Run Pharmaceuticals, LLC); the NDA 21169 record on Drugs@FDA; every galantamine label on DailyMed.
Highlights of the record
FDA label of June 1, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageGalantamine tablets are indicated for the treatment of mild to moderate dementia of the Alzheimer’s type.
Forms and strengths
- 4 mg
- 8 mg
- 12 mg
- 16 mg
- 24 mg
- 4 mg/ml
Film-coated tablet; extended-release capsule; solution.
On the market
- Earliest approval on file
- February 28, 2001 Razadyne, Janssen Pharms; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 19 first August 28, 2008; 11 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 9 of which 9 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.294 per tablet Galantamine hbr 4 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 3,188 through July 30, 2026
What is galantamine used for?
From the label: indications and usageGalantamine tablets are indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. Galantamine Tables are a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type
Conditions named in the indications of galantamine's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Cholinesterase Inhibitor.
Source: FDA drug label (Galantamine), Slate Run Pharmaceuticals, LLC, effective June 1, 2026 (SPL set 56f365e5-0a23-4f69-e054-00144ff8d46c), via openFDA; the full label on DailyMed
Is there a generic for galantamine (Razadyne)?
The FDA approved the first generic galantamine on August 28, 2008. 19 generic applications are approved; 11 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale. Drugs@FDA also holds 3 tentative approvals: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
FDA's NDC Directory lists galantamine from 9 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 2001 earliest approval on file
- 2008 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for galantamine (Razadyne)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.294 per Galantamine hbr 4 mg tablet, down 10% from $0.327 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Galantamine hbr 4 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Galantamine ER 16 mg capsule | Generic | $0.846 per capsule | $25.38 | -14% |
| Galantamine ER 24 mg capsule | Generic | $0.905 per capsule | $27.15 | -18% |
| Galantamine ER 8 mg capsule | Generic | $0.802 per capsule | $24.07 | -6% |
| Galantamine hbr 12 mg tablet | Generic | $0.513 per tablet | $15.38 | -11% |
| Galantamine hbr 4 mg tablet | Generic | $0.294 per tablet | $8.82 | -10% |
| Galantamine hbr 8 mg tablet | Generic | $0.402 per tablet | $12.05 | +8% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the galantamine label say about other medicines?
The galantamine label names 2 other medicines in its interaction, contraindication or warning sections. The labels of 2 other medicines name galantamine. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Bethanechol | drug interactions | Cholinomimetics and Other Cholinesterase Inhibitors A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol [see Clinical Pharmacology (12.3) ]. |
| Succinylcholine | drug interactions | DRUG INTERACTIONS Potential to interfere with the activity of anticholinergic medications ( 7.1 ) Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists |
Other labels that name galantamine
Source: FDA drug label (Galantamine), Slate Run Pharmaceuticals, LLC, effective June 1, 2026 (SPL set 56f365e5-0a23-4f69-e054-00144ff8d46c), via openFDA; the full label on DailyMed
What do FAERS reports show for galantamine?
The FDA Adverse Event Reporting System holds 3,188 reports that list galantamine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 342 are coded as a death and 1,681 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as galantamine?
4 other medicines are given the same way (oral) and in the same FDA class as galantamine or labeled mainly for the same use (alzheimer's disease), the same class first. Alzheimer's disease lists all 7 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Donepezil | Alzheimer's disease | 31 labelers | $0.0484 per tablet 10 mg tablet | No current entry |
| Rivastigmine | Alzheimer's disease | 11 labelers | $0.164 per capsule 1.5 mg capsule | A presentation being discontinued |
| Donepezil and memantine | Alzheimer's disease | 5 labelers | $8.44 per unit 28-10 mg | A presentation being discontinued |
| Memantine | Alzheimer's disease | 38 labelers | $0.063 per tablet 10 mg tablet | No current entry |
Every medicine labeled for the same conditions as galantamine
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does galantamine compare with medicines for the same use?
3 side-by-side pages set galantamine beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to galantamine
- 4 medicines for the same use
- Other cholinesterase inhibitors
- the pharmacologic class, with prices and generics
- Galantamine side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other